
CLOV Stock Forecast & Price Target
CLOV Analyst Ratings
Bulls say
Clover Health Investments Corp reported a substantial 53% year-over-year growth in Medicare Advantage membership during the annual enrollment period, reaching approximately 153,000 members, which bolsters confidence in the company's ongoing market presence. The introduction of a 4.0-Star reimbursement plan for 2026, along with anticipated improvements in new member revenue exceeding $70 PMPM, is expected to significantly enhance contribution margins. Additionally, improved medical cost ratios driven by the Clover Assistant platform are projected to yield better unit economics and margin contributions as the company expands its membership and scales in its core markets.
Bears say
Clover Health Investments Corp faces significant challenges that contribute to a negative outlook on its stock, primarily due to lower-than-expected retention of 4-Star ratings, which could impact future Medical Loss Ratios (MLR) and earnings projections. The company’s guidance suggests potential declines in gross profit margins driven by new membership dilution, while uncertainties surrounding regulatory changes and market dynamics in the Medicare Advantage landscape further complicate its financial position. Additionally, the reliance on its Clover Assistant to manage MLR trends poses risks, as any negative developments could tarnish investor confidence and provoke downward revisions in consensus forecasts.
This aggregate rating is based on analysts' research of Clover Health Investments and is not a guaranteed prediction by Public.com or investment advice.
CLOV Analyst Forecast & Price Prediction
Start investing in CLOV
Order type
Buy in
Order amount
Est. shares
0 shares